Stockscreener 앱 받기
39.74
3.40%
-1.40
시간 외 거래:
39.74
전일 마감가:
$41.14
열려 있는:
$40.84
하루 거래량:
824.29K
Relative Volume:
1.26
시가총액:
$2.27B
수익:
-
순이익/손실:
$-100.44M
주가수익비율:
-18.50
EPS:
-2.1478
순현금흐름:
$-105.32M
1주 성능:
+6.14%
1개월 성능:
-7.56%
6개월 성능:
+1.15%
1년 성능:
-43.13%
1일 변동 폭
$39.40
$42.22
1주일 범위
$37.24
$42.57
52주 변동 폭
$26.61
$72.16
Structure Therapeutics Inc Adr Stock (GPCR) Company Profile
명칭
Structure Therapeutics Inc Adr
전화
(628) 229-9277
주소
611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO
Structure Therapeutics Inc Adr Stock (GPCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-21 | 개시 | JP Morgan | Overweight |
| 2024-04-09 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2023-07-27 | 개시 | Piper Sandler | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2023-02-28 | 개시 | BMO Capital Markets | Outperform |
| 2023-02-28 | 개시 | Guggenheim | Buy |
| 2023-02-28 | 개시 | Jefferies | Buy |
| 2023-02-28 | 개시 | SVB Securities | Outperform |
모두보기
Structure Therapeutics Inc Adr 주식(GPCR)의 최신 뉴스
abrdn plc Has $9.53 Million Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Ballard Power Systems Inc (NASDAQ: BLDP) Has Great Upside Potential - Stocks Register
Is Structure Therapeutics Inc ADR (NASDAQ: GPCR) A Good Investment For New Investors Now? - Stocks Register
10 Best IPO Stocks To Buy Heading into 2025 - Insider Monkey
Biopharma Co. Can't Knock Ex-CFO's Bias Suit Out Of Court - Law360
Armata Pharmaceuticals Announces Structural Biology Publication - StockTitan
Some of the Major Key Players in the oral proteins and peptides market are - InsightAce Analytic
Secretome Therapeutics, Inc. Announces Composition of Matter Patents for Lead Assets STM-01 and STM-21 - Business Wire
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $86.80 - MarketBeat
GPCR drugmaker Septerna amasses $288M in IPO - BioPharma Dive
Griffin Asset Management Inc. Acquires New Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Exchange Traded Concepts LLC Has $1.80 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR Inc. (GPCR) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
Daily Progress: Structure Therapeutics Inc ADR (GPCR) Drop -1.39, Closing at 38.32 - The Dwinnex
Is Structure Therapeutics Inc ADR (GPCR) a threat to investors? - US Post News
Structure Therapeutics (NASDAQ:GPCR) Shares Down 2.7%Here's What Happened - MarketBeat
Structure Therapeutics Inc ADR: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Top investors say Structure Therapeutics Inc ADR (GPCR) ticks everything they need - SETE News
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch. - BioPharma Dive
Weight Loss Drugs Market Top Trends 2024-2031 - InsightAce Analytic
Market Recap Check: Structure Therapeutics Inc ADR (GPCR)’s Positive Finish at 40.50, Up/Down 0.30 - The Dwinnex
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect? - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Shares Up 3.7%Here's What Happened - MarketBeat
The Manufacturers Life Insurance Company Buys 32,839 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics Inc ADR (GPCR) is a good investment, but the stock may be overvalued - US Post News
27,094 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by Bank of Montreal Can - MarketBeat
35,700 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Renaissance Technologies LLC - Defense World
Marshall Wace LLP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
3 AI Stocks to Buy as Nvidia Sputters - InvestorPlace
Are Structure Therapeutics Inc ADR (GPCR) shares a good deal now? - US Post News
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Structure Therapeutics Inc. (NASDAQ:GPCR) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Confo Therapeutics Announces Publication in Nature Communications Demonstrating First-Ever Structure of a Complex Between an Antibody-based Agonist and a Class A GPCR Regulating Hunger and Satiety - Yahoo Finance
Structure Therapeutics (NASDAQ:GPCR) Trading 5.8% Higher - MarketBeat
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer - BioSpace
Nasdaq Global Select Market Composite Index (NQGS) QuotePress Release - The Globe and Mail
S&P 100 Index (OEX) QuotePress Release - The Globe and Mail
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
Ratios Uncovered: Breaking Down Structure Therapeutics Inc ADR (GPCR)’s Trailing Twelve Months Metrics - The Dwinnex
Structure Therapeutics Inc ADR (GPCR) expanding its growth trajectory ahead - SETE News
Perceptive Advisors LLC Makes New Investment in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Perceptive Advisors LLC Acquires Shares of 34,852 Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Structure Therapeutics' SWOT analysis: small-cap biotech's stock potential in obesity market - Investing.com
This Weight-Loss Stock Just Scored A New Street-High Price Target - Barchart
18,803 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Purchased by Scientech Research LLC - MarketBeat
Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now? - Insider Monkey
Driehaus Capital Management LLC Has $101.20 Million Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) - MarketBeat
Closing Figures Unveiled: Structure Therapeutics Inc ADR (GPCR) Drop -4.70, Closes at 41.95 - The Dwinnex
183,785 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Bought by Ensign Peak Advisors Inc - MarketBeat
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? - Morningstar
Structure Therapeutics Inc Adr (GPCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.11%
0.50%
자본화:
|
볼륨(24시간):